Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H17N4OS.Cl.ClH |
Molecular Weight | 337.269 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC2=CN=C(C)N=C2N
InChI
InChIKey=DPJRMOMPQZCRJU-UHFFFAOYSA-M
InChI=1S/C12H17N4OS.2ClH/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;;/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);2*1H/q+1;;/p-1
Molecular Formula | C12H16N4OS |
Molecular Weight | 264.347 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Thiamine, also known as vitamin B1, plays a key role in the human metabolism. It is present in many dietary sources such as meats, eggs, fish, beans and peas, nuts, and whole grains. Upon administration thiamine is converted by thiamine
pyrophosphokinase-1 (TPK1) to the active form, thiamine pyrophosphate, which serves as a cofactor for enzymes involved in the TCA cycle and the non-oxidative part of the pentose phosphate pathway. The lack of thiamine may cause the thiamine deficiency. The classical syndrome caused primarily by thiamine deficiency in humans is beriberi, however, symptoms of thiamine deficiency also include congestive heart failure, metabolic acidosis, confusion, ataxia and seizures. Thiamine is a component of many vitamin complexes, which are approved for the treatmen and prevention of general vitamin deficiency, including the thiamine deficiency.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7120152
Curator's Comment: The transport of thiamine across the blood brain barrier was shown in rats.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q9H3S4 Gene ID: 27010.0 Gene Symbol: TPK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16550223 |
|||
Target ID: GO:0005975 |
|||
Target ID: WP408 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | M.V.I.-12 Approved UseM.V.I.-12 Unit Vial, is indicated for the prevention of vitamin deficiency in adults and children aged 11 years and above who are on warfarin anticoagulant therapy receiving home parenteral nutrition. Launch Date1953 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
386 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
40 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
95 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
39 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
397 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
113 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2046 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
214 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
623 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
177 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2059 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
612 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
Sources: https://go.drugbank.com/drugs/DB00152 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00152 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://go.drugbank.com/drugs/DB00152 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Thiamine for Alzheimer's disease. | 2001 |
|
[Evaluation of vitamin and immune status of patients with chronic palatal tonsillitis]. | 2001 |
|
Effects of vitamins on hepatic nuclear binding of L-tryptophan. | 2001 |
|
Rapid diagnosis of alcoholic ketoacidosis by proton NMR. | 2001 Apr |
|
Severe metabolic acidosis and heart failure due to thiamine deficiency. | 2001 Apr |
|
Do breastfed infants need supplemental vitamins? | 2001 Apr |
|
Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. | 2001 Apr |
|
[Chronic alcohol abuse. Benfotiamine in alcohol damage is a must]. | 2001 Apr 19 |
|
The multifaceted and widespread pathology of magnesium deficiency. | 2001 Feb |
|
Consequences of a modified putative substrate-activation site on catalysis by yeast pyruvate decarboxylase. | 2001 Feb 13 |
|
Inhibitors of advanced glycation end product-associated protein cross-linking. | 2001 Feb 14 |
|
Reaction mechanism for mammalian pyruvate dehydrogenase using natural lipoyl domain substrates. | 2001 Feb 15 |
|
Molecular cloning of human thiamin pyrophosphokinase. | 2001 Jan 26 |
|
Isolation and characterization of a human thiamine pyrophosphokinase cDNA. | 2001 Jan 26 |
|
Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport. | 2001 Jan-Feb |
|
Use of vitamin supplements and cataract: the Blue Mountains Eye Study. | 2001 Jul |
|
Low thiamine intake and risk of cataract. | 2001 Jul |
|
Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. | 2001 Jul |
|
Mechanism of thiamine uptake by human colonocytes: studies with cultured colonic epithelial cell line NCM460. | 2001 Jul |
|
Sulphoacetaldehyde sulpho-lyase (EC 4.4.1.12) from Desulfonispora thiosulfatigenes: purification, properties and primary sequence. | 2001 Jul 15 |
|
No association between DLST gene and Alzheimer's disease or Wernicke-Korsakoff syndrome. | 2001 Jul-Aug |
|
The crystal structure of yeast thiamin pyrophosphokinase. | 2001 Jun |
|
Vitamin B intake and status in healthy Havanan men, 2 years after the Cuban neuropathy epidemic. | 2001 Jun |
|
Nutritional status in elderly female hip fracture patients: comparison with an age-matched home living group attending day centres. | 2001 Jun |
|
Sulfur compounds reduce potato toxins during extrusion cooking. | 2001 Jun |
|
Vitamin B1 and B6 retention in milk after continuous-flow microwave and conventional heating at high temperatures. | 2001 Jun |
|
Slc19a2: cloning and characterization of the murine thiamin transporter cDNA and genomic sequence, the orthologue of the human TRMA gene. | 2001 Jun |
|
Simultaneous determination of thiamine and pyridoxine in pharmaceuticals by using a single flow-through biparameter sensor. | 2001 Jun |
|
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. | 2001 Jun |
|
Comparison of ion-pair and amide-based column reversed-phase liquid chromatography for the separation of thiamine-related compounds. | 2001 Jun 15 |
|
Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. | 2001 Jun 26 |
|
Catalytic acid-base groups in yeast pyruvate decarboxylase. 1. Site-directed mutagenesis and steady-state kinetic studies on the enzyme with the D28A, H114F, H115F, and E477Q substitutions. | 2001 Jun 26 |
|
Crystal structure of thiamin pyrophosphokinase. | 2001 Jun 29 |
|
Relationships between dietary intake and cognitive function level in Korean elderly people. | 2001 Mar |
|
Wernicke's encephalopathy in patients with hyperemesis gravidarum. | 2001 Mar |
|
[Shoshin beriberi: myth or reality?]. | 2001 Mar |
|
The genes for anabolic 2-oxoglutarate: ferredoxin oxidoreductase from Hydrogenobacter thermophilus TK-6. | 2001 Mar 30 |
|
[Metabolic characteristics of the Yarrowia lipolytica strain producing alpha-ketoglutaric and citric acids from ethanol and the effect of [NH4+] and [O2] on yeast respiration and biosynthesis]. | 2001 Mar-Apr |
|
[Other drugs administered with TPN solution]. | 2001 May |
|
[Solutions for the hyperalimentation]. | 2001 May |
|
The application of capillary electrophoresis to the analysis of vitamins in food and beverages. | 2001 May |
|
Pharmacotherapy of mental illness--a historical analysis. | 2001 May |
|
Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo-degenerative ataxias. | 2001 May |
|
A novel mutation in the SLC19A2 gene in a Tunisian family with thiamine-responsive megaloblastic anaemia, diabetes and deafness syndrome. | 2001 May |
|
Early recognition of acute cardiovascular beriberi by interpretation of hemodynamics. | 2001 May |
|
Wernicke's encephalopathy in a non-alcoholic man: case report and brief review. | 2001 May |
|
Stability of thiamine and vitamins E and A during storage of enteral feeding formula. | 2001 May |
|
The bio operon on the acquired symbiosis island of Mesorhizobium sp. strain R7A includes a novel gene involved in pimeloyl-CoA synthesis. | 2001 May |
|
Application of liquid chromatography to the simultaneous determination of acetylsalicylic acid, caffeine, codeine, paracetamol, pyridoxine, and thiamine in pharmaceutical preparations. | 2001 May-Jun |
|
The role of the cysteine residues of ThiI in the generation of 4-thiouridine in tRNA. | 2001 Sep 7 |
Patents
Sample Use Guides
The starting dose (as a component of M.V.I.–12) is one 10 mL daily dose added directly to an intravenous fluid.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10516094
Human Caco-2 cells were incubated (37 Celsius) in Krebs-Ringer buffer (pH 7.4) for different periods of time in the presence of 0.1 uM and 10 uM thiamine. The uptake study demonstrated that thiamine is transported across the cell membrane with Michaelis-Menten constant of 3.18 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:24:26 GMT 2023
by
admin
on
Fri Dec 15 17:24:26 GMT 2023
|
Record UNII |
M572600E5P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 310.529
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
||
|
NCI_THESAURUS |
C26017
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
||
|
CFR |
21 CFR 184.1875
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
||
|
JECFA EVALUATION |
THIAMINE HYDROCHLORIDE
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
||
|
DSLD |
2667 (Number of products:2178)
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6202
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
963
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
DTXSID0040622
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
M572600E5P
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
m10717
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
49105
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
SUB04798MIG
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
200-641-8
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
100000091092
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
235355
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | RxNorm | ||
|
36226
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
1656002
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
DBSALT000205
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
M572600E5P
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
THIAMINE HYDROCHLORIDE
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | Description: Colourless crystals or a white or yellowish white, crystalline powder; odour, slight and characteristic. Solubility: Soluble in 1 part of water and in 100 parts of ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Component of vitamin B. Storage: Thiamine hydrochloride should be kept in a tightly closed, non-metallic container, protected from light. Additional information: Even in the absence of light, Thiamine hydrochloride is gradually degraded on exposure to a humidatmosphere, the decomposition being faster at higher temperatures. When exposed to air, the anhydrous product rapidly absorbsabout 4 g of water per 100 g. Melting temperature, about 248 ?C with some decomposition. In solution at pH 4.0 or less, it loses its activity only very slowly. Neutral and alkaline solutions deteriorate rapidly, especially in contact with air. Definition: Thiamine hydrochloride contains not less than 98.0% and not more than 101.0% of C12H17ClN4OS,HCl, calculated with reference to the dried substance. | ||
|
C48025
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
67-03-8
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL1547
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY | |||
|
SUB179894
Created by
admin on Fri Dec 15 17:24:27 GMT 2023 , Edited by admin on Fri Dec 15 17:24:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |